Cancer incidence in patients with hereditary hemorrhagic telangiectasia
详细信息 查看全文
- 作者：Christine W. Duarte ; Adam W. Black…
- 关键词：SEER Medicare ; Endoglin ; HHT ; Case–control ; Cancer incidence
- 刊名：Journal of Cancer Research and Clinical Oncology
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：143
- 期：2
- 页码：209-214
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Oncology; Cancer Research; Internal Medicine; Hematology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-1335
- 卷排序：143
文摘
PurposeHereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by deficiency in endoglin, an angiogenic protein. We previously showed that HHT, in which systemic endoglin expression is reduced, was associated with better survival outcomes in cancer patients (Duarte et al. in Cancer Epidemiol Biomarkers Prev 23:117–125, 2014). Here, we evaluated whether HHT was associated with reduced cancer incidence.